Cholangiocarcinoma News

Important Role of Screening for Genomic Alterations in Cholangiocarcinoma

September/October 2021, Vol 2, No 3

Comprehensive molecular profiling has demonstrated a diverse landscape of oncogenic genomic alterations in cholangiocarcinoma (CCA), which are often the drivers of CCA. In a recent review article, Tanios S. Bekaii-Saab, MD, FACP, Vice Chair and Section Chief for Medical Oncology, Department of Internal Medicine, Mayo Clinic Cancer Center, Phoenix, AZ, and colleagues provided an overview of the molecular heterogeneity of CCA, discussing the role of molecular tests for the diagnosis of patients with intrahepatic CCA, and the implications of the genomic alterations in the treatment of patients with this aggressive disease.

Intrahepatic CCA has a unique molecular landscape, such as IDH1 mutation and FGFR2 fusion or other alterations, that is not often seen in other solid tumors, the authors noted. The most common genetic alterations include TP53 mutations, CDKN2A/B loss, and KRAS mutations.

Studies have identified important differences between the molecular landscapes of intrahepatic CCA and extrahepatic CCA. For example, IDH1 mutations are found in up to 29% of patients with intrahepatic CCA and FGFR2 rearrangements are found in approximately 10% of patients, but those are rare in patients with extrahepatic CCA.

FGFR2 fusion or rearrangements and IDH1 mutation are currently the only genetic alterations in CCA for which targeted therapies have been approved. Large-scale genomic profiling also identified many other alterations for which targeted therapies are approved in other indications.

“Given the paucity of current treatment options and the limited effectiveness of standard chemotherapy in CCA, ‘molecular diagnosis’ provides an important opportunity for improved personalized treatment plans in CCA,” Bekaii-Saab and colleagues suggested.

Advances in next-generation sequencing (NGS) have allowed large gene panels to be assayed with high sensitivity, specificity, accuracy, and speed. Thanks to the progress in sequencing technologies in the past decade, turnaround times for NGS-based assays can produce results within 1 to 3 weeks.

Available tests vary regarding acceptable source material, genetic source for library construction, target selection technology, gene panel size, and type of detectable genomic alterations. NGS-based assays include FDA-cleared or FDA-approved in vitro diagnostic tests or internally validated laboratory tests.

Currently, several tumor profiling assays have been cleared or approved by the FDA for use as an in vitro diagnostic test, with panels of up to several hundred genes.

“Most patients with iCCA [intrahepatic CCA] have only limited biopsy sample available for molecular profiling; NGS allows the detection of multiple biomarkers in a single analysis, thus reducing the amount of tissue needed for testing,” Bekaii-Saab and colleagues observed.

The current cost of the NGS-based molecular profiling tests varies considerably. The authors noted a paucity of real-world evidence for the cost-effectiveness of NGS in routine clinical practice. However, the coverage of policies and private and government payers are starting to include NGS-based testing, particularly with recent FDA approvals of NGS-based companion diagnostic tests.

Transcriptomics, proteomics, and metabolomics may also provide vital information to improve treatment stratification of patients with CCA.

“The recent successes and continuing efforts in the development of targeted therapies for patients with CCA suggest that genomic profiling will become an integral diagnostic tool to guide treatment decisions in CCA,” Bekaii-Saab and colleagues concluded. “However, future development of precision medicine in CCA will likely require the integration of information from multiple omics approaches.”

Source: Bekaii-Saab TS, Bridgewater J, Normanno N. Practical considerations in screening for genetic alterations in cholangiocarcinoma. Ann Oncol. 2021;32:1111-1126.

Related Items

Cross-Comparison of Clinical Trials Assessing Futibatinib and Pemigatinib versus Chemotherapy in Patients with CCA and FGFR2 Fusion or Other Rearrangements
2022 Year in Review: Cholangiocarcinoma
A comparison of clinical trials found progression-free survival with futibatinib to be significantly greater compared with chemotherapy and that trials favor futibatinib over pemigatinib for all efficacy parameters.
Utility of Liquid Biopsy for Identification of Molecular Alterations in Solid Tumors
2022 Year in Review: Cholangiocarcinoma
Real-world evidence supports a role for liquid biopsy in identifying molecular alterations and offering personalized treatment options, with IDH1 identified in a patient with cholangiocarcinoma.
Preliminary Analyses of QOL Data from the ABC-06 Clinical Trial
2022 Year in Review: Cholangiocarcinoma
Preliminary quality-of-life data suggest a potentially positive impact of L-folinic acid plus oxaliplatin plus 5-fluorouracil when used in conjunction with active symptom control.
NALIRICC Study of Nanoliposomal Irinotecan Combination Therapy in Metastatic BTC
2022 Year in Review: Cholangiocarcinoma
The NALIRICC study did not meet overall survival or progression-free survival end points, with nanoliposomal irinotecan plus 5-fluorouracil falling short in patients with metastatic biliary tract cancer.
Tislelizumab plus GemOx and Lenvatinib as a Conversion Therapy Regimen for Potentially Resectable BTCs
2022 Year in Review: Cholangiocarcinoma
The combination of tislelizumab, lenvatinib, and gemcitabine/oxaliplatin was shown to be promising as a conversion therapy for patients with potentially resectable locally advanced biliary tract cancer in this phase 2 study.
Health-Related QOL Study in Patients with CCA
2022 Year in Review: Cholangiocarcinoma
Study revealed increased financial toxicities in patients with cholangiocarcinoma enrolled in clinical trials and receiving targeted therapies.
Updated Analysis of the LUC2001 Study
2022 Year in Review: Cholangiocarcinoma
Erdafitinib was found to be associated with durable efficacy and manageable toxicity in Asian patients with advanced cholangiocarcinoma with FGFR alterations.
Biliary Tract Cancers: Is Laparoscopic Liver Resection Adequate?
2022 Year in Review: Cholangiocarcinoma
Study finds laparoscopic liver resection was associated with less blood loss and shorter length of stay compared with open liver resection.
The Future of Neoadjuvant Chemotherapy for iCCA
2022 Year in Review: Cholangiocarcinoma
Study found lower rates of margin-positive resection of intrahepatic cholangiocarcinoma with neoadjuvant chemotherapy.
Mayo Clinic Study Assessed Impact of Neoadjuvant Chemoradiation in Patients with Unresectable Perihilar CCA
2022 Year in Review: Cholangiocarcinoma
Neoadjuvant chemoradiation was found to elicit no differences in survival among patients with unresectable perihilar cholangiocarcinoma.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: